FindTrial
Sign In

Efficacy of tight control of Infliximab (IFX) for Crohn's disease (CD) by CRP value and fecal concentration of calprotectin (Quattro C study)

Efficacy of tight control of Infliximab (IFX) for Crohn's disease (CD) by CRP value and fecal concentration of calprotectin (Quattro C study) - Investigation of efficacy of tight control or withdrawal of Infliximab (IFX) for Crohn's disease (CD) by CRP value and fecal concentration of calprotectin

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000011820
Enrollment
20
Registered
2013-10-01
Start date
2013-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

Withdrawal of IFX for patients with clinical remission and negative of CRP value Resume or dose increase of IFX for patients with consecutive positive of CRP value or fecal concentration of calprotect

Sponsors

NationalOrganizationHospital Fukuyama medical center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients receiving IFX more than 3 times previously

Exclusion criteria

Exclusion criteria: Patients receiving IFX with 10 mg/kg dose Patients receiving IFX at interval of less than 6 weeks

Design outcomes

Primary

MeasureTime frame
Clinical remission rate after 104 weeks (Interim analysis performed in 52 weeks)—

Secondary

MeasureTime frame
Correlation with change of IFX dose and CRP value or fecal concentration of calprotectin—

Countries

Japan

Contacts

Public ContactTatsuya Toyokawa

NationalOrganizationHospital Fukuyama medical center Department of Gastroenterology

toyotatu@kmail.plala.or.jp084-922-0001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026